Work

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

Year: 1997

Type: review

Abstract: The platelet glycoprotein GPIIb/IIIa ( ␣ IIb ␤ 3 ) antagonist c7E3 Fab (the Fab fragment of the mouse/human chimeric monoclonal antibody 7E3; abciximab; ReoPro™) was approved for human use in the United States in December 1994 based on its safety and its efficacy in reducing the risk of ischemic complications after percutaneous coronary intervention (PCI; 1 angioplasty or atherectomy) (1, 2).The success of this agent reflects our emerging ability to identify adhesion molecules as therapeutic targets, and then construct effective inhibitors that meet the stringent safety standards required for a new drug.As the first rationally designed antiplatelet and anti-integrin receptor drug, c7E3 Fab serves as a prototype for other anti-integrin receptor, and more generally, antiadhesion receptor, agents designed to treat and/or prevent human disease.

Source: Journal of Clinical Investigation

DOI: 10.1172/jci119307

Author: B S Coller

Institution: Icahn School of Medicine at Mount Sinai

Language: English

Topic: Cell Adhesion Molecules Research

Subfield: Immunology and Allergy

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Public Health Service, National Heart, Lung, and Blood Institute